These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15277257)

  • 41. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.
    Hensing TA; Hanna NH; Gillenwater HH; Gabriella Camboni M; Allievi C; Socinski MA
    Anticancer Drugs; 2006 Jul; 17(6):697-704. PubMed ID: 16917215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study.
    Felip E; Rosell R; Domine M; Santomé L; Garrido P; Font A; Carrato A; Terrasa J; Vadell C; Mañe JM; Baselga J;
    Ann Oncol; 2003 Oct; 14(10):1549-54. PubMed ID: 14504057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777.
    Wright J; Blatner GL; Cheson BD
    Oncology (Williston Park); 1999 Nov; 13(11):1527, 1530, 1533. PubMed ID: 10581601
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.
    Schwandt A; Mekhail T; Halmos B; O'Brien T; Ma PC; Fu P; Ivy P; Dowlati A
    J Thorac Oncol; 2012 Apr; 7(4):751-4. PubMed ID: 22425925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
    Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
    J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
    J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
    Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
    Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.
    Caraglia M; Marra M; Viscomi C; D'Alessandro AM; Budillon A; Meo G; Arra C; Barbieri A; Rapp UR; Baldi A; Tassone P; Venuta S; Abbruzzese A; Tagliaferri P
    Int J Cancer; 2007 Nov; 121(10):2317-30. PubMed ID: 17657738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
    Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
    Skarlos DV; Samantas E; Briassoulis E; Panoussaki E; Pavlidis N; Kalofonos HP; Kardamakis D; Tsiakopoulos E; Kosmidis P; Tsavdaridis D; Tzitzikas J; Tsekeris P; Kouvatseas G; Zamboglou N; Fountzilas G
    Ann Oncol; 2001 Sep; 12(9):1231-8. PubMed ID: 11697833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.
    Venkatasubbarao K; Choudary A; Freeman JW
    Cancer Res; 2005 Apr; 65(7):2861-71. PubMed ID: 15805288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777.
    Gunning WT; Kramer PM; Lubet RA; Steele VE; End DW; Wouters W; Pereira MA
    Clin Cancer Res; 2003 May; 9(5):1927-30. PubMed ID: 12738751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.
    Whitehead RP; McCoy S; Macdonald JS; Rivkin SE; Neubauer MA; Dakhil SR; Lenz HJ; Tanaka MS; Abbruzzese JL;
    Invest New Drugs; 2006 Jul; 24(4):335-41. PubMed ID: 16683076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.
    Graziano SL; Herndon JE; Socinski MA; Wang X; Watson D; Vokes E; Green MR;
    J Thorac Oncol; 2008 Feb; 3(2):158-62. PubMed ID: 18303437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
    Fenaux P; Raza A; Mufti GJ; Aul C; Germing U; Kantarjian H; Cripe L; Kerstens R; De Porre P; Kurzrock R
    Blood; 2007 May; 109(10):4158-63. PubMed ID: 17264294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra MT).
    Alyaqoub FS; Tao L; Kramer PM; Steele VE; Lubet RA; Gunning WT; Pereira MA
    Carcinogenesis; 2007 Jan; 28(1):124-9. PubMed ID: 16885199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
    Lee JE; Park HS; Jung SS; Kim JO; Kim SY
    Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A; Gray LA; Reeder T; Schroeder G; Kaufmann SH
    Leukemia; 2003 May; 17(5):849-55. PubMed ID: 12750696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
    Rossman J; Reddy V; Cantor A; Miley D; Robert F
    Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.